Structural and functional basis of antinociceptive action of chi-conotoxin AoIA at the noradrenaline transporter.
Belleza, O.J.V., Zhang, H., Schmidhammer, H., Gonzalez, T.I., Ciotu, C.I., Tomasevic, N., Ocampo, C.M.M., Fernando, J.C., Koehbach, J., Schwarz, P., Al Makhlouf, M., Tajti, G., Hasinger, S., Kastner, N., Avsar, O., Retzl, B., Jantsch, K., Jiang, Y., Hellinger, R., Fischer, M.J.M., Rosengren, K.J., Gruber, C.W., Villaraza, A.J.L., Stockner, T., Spetea, M., Xu, H.E., Sitte, H.H.(2026) Nat Struct Mol Biol 
- PubMed: 42481720 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41594-026-01838-z
- Primary Citation Related Structures: 
9K6X, 9PAZ, 9PB0 - PubMed Abstract: 
The χ-conotoxins are venom-derived peptides that specifically target the noradrenaline transporter (also known as norepinephrine transporter, NET). Regulation of noradrenergic signaling by NET affects neurophysiological processes, including pain. Therefore, the χ-conotoxin MrIA and its synthetic analogs have been previously investigated for their analgesic activity. Here we describe the synthesis and pharmacological characterization of χ-AoIA, a peptide that selectively inhibits NET with a higher potency compared to MrIA in in vitro radiotracer flux assays. Furthermore, we resolved the structure of the human NET:χ-AoIA complex by cryogenic electron microscopy, which revealed an atypical binding mode consisting of both the central binding site and the outer vestibule of the transporter. Lastly, χ-AoIA displays antinociceptive efficacy in a model of inflammatory pain after subcutaneous administration in mice. Our results demonstrate the efficacy of χ-AoIA as a highly selective ligand of NET and provide a mechanistic basis for its potential development as a nonopioid analgesic.
- Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Organizational Affiliation: 
















